Lung Cancer: Targets and Therapy : Impact Factor & More
eISSN: 1179-2728pISSN: 1179-2728
Open AccessShare this on:
Key Metrics
CiteScore 
6.5
SNIP
1.15
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Lung Cancer: Targets and Therapy Journal Specifications
Indexed in the following public directories
Web of Science 
Scopus 
DOAJ 
SJR
| Overview | |
| Publisher | DOVE MEDICAL PRESS LTD |
| Language | English |
| Frequency | Continuous publication |
| Article Processing Charges | USD 2390 |
| Publication Time | 16 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Frequency | Continuous publication |
| Publication Start Year | 2008 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC BY-NC |
| OA statement | Visit website |
View less
Planning to publish in Lung Cancer: Targets and Therapy ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Lung Cancer: Targets and Therapy
Sunvozertinib in EGFR Exon 20 Insertion NSCLC: Approved but Not Available \u2013 Practical Dose Selection Considerations and Real-World Access Challenges
- 28 May 2026
- Lung Cancer: Targets and Therapy
Response to Selpercatinib in a CCDC6-RET Lung Adenocarcinoma with an Acquired Novel RET p.L730_G731insL After Progression on Pralsetinib: A Case Report
- 20 May 2026
- Lung Cancer: Targets and Therapy
HER2-ADC and HER2-TKI Overcomes HER2 Amplification as an Acquired Resistance to Zongertinib \u2013 A Case Report
- 14 May 2026
- Lung Cancer: Targets and Therapy
Exploratory Identification of Gene Copy Number Cut-Off for NGS-Based MET Amplification Assessment and Clinical Relevance to MET Inhibitor Outcomes in Non-Small-Cell Lung Cancer
- 8 May 2026
- Lung Cancer: Targets and Therapy
Efficiency of Immunological Blood Biomarkers in Predicting Chemotherapy Response and Survival Outcome for Non-Targetable Advanced Non-Small Cell Lung Cancer Patients
- 16 Mar 2026
- Lung Cancer: Targets and Therapy
Prospective Observational Real-World Study of Afatinib as First-Line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in China.
- 1 Feb 2026
- Lung Cancer (Auckland, N.Z.)
Sunvozertinib in EGFR Exon 20 Insertion NSCLC: Approved but Not Available \u2013 Practical Dose Selection Considerations and Real-World Access Challenges
- 28 May 2026
- Lung Cancer: Targets and Therapy
Response to Selpercatinib in a CCDC6-RET Lung Adenocarcinoma with an Acquired Novel RET p.L730_G731insL After Progression on Pralsetinib: A Case Report
- 20 May 2026
- Lung Cancer: Targets and Therapy
HER2-ADC and HER2-TKI Overcomes HER2 Amplification as an Acquired Resistance to Zongertinib \u2013 A Case Report
- 14 May 2026
- Lung Cancer: Targets and Therapy
Exploratory Identification of Gene Copy Number Cut-Off for NGS-Based MET Amplification Assessment and Clinical Relevance to MET Inhibitor Outcomes in Non-Small-Cell Lung Cancer
- 8 May 2026
- Lung Cancer: Targets and Therapy
Efficiency of Immunological Blood Biomarkers in Predicting Chemotherapy Response and Survival Outcome for Non-Targetable Advanced Non-Small Cell Lung Cancer Patients
- 16 Mar 2026
- Lung Cancer: Targets and Therapy
Prospective Observational Real-World Study of Afatinib as First-Line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in China.
- 1 Feb 2026
- Lung Cancer (Auckland, N.Z.)
FAQs on Lung Cancer: Targets and Therapy
How long has Lung Cancer: Targets and Therapy been actively publishing? 
What is the publishing frequency of Lung Cancer: Targets and Therapy?
How many articles did Lung Cancer: Targets and Therapy publish last year?
What is the eISSN & pISSN for Lung Cancer: Targets and Therapy?
What is Citescore for Lung Cancer: Targets and Therapy?
What is SNIP score for Lung Cancer: Targets and Therapy?
Who is the publisher of Lung Cancer: Targets and Therapy?
